Toll-like receptor (TLR)-4 agonists have been shown to trigger host resistance to infection that lasts for up to two weeks in several clinically relevant models of infection (10, 11, 15), which our group has revealed to be driven by long-term changes in innate immune function supported by metabolic rewiring (13). The gene discussed is TLR4; the disease is infection.